Exhibit 10.14
-------------
December 31, 2001
Xxxxxxx X. XxXxxxxx
Senior Vice President and Chief Financial Officer
Bausch & Lomb Incorporated
Xxx Xxxxxx & Xxxx Xxxxx
Xxxxxxxxx, Xxx Xxxx 00000
Dear Xxxxx:
Reference is made to the License Agreement between Control Delivery Systems,
Inc. and Bausch & Lomb Incorporated dated as of June 9, 1999, as amended (the
"Agreement"). Defined terms shall have the meanings set forth in the Agreement.
As we discussed, please sign below to indicate Bausch and Lomb's agreement that:
(a) Exhibit 6.1 is the modified Budget that sets forth for the period from
June 9, 1999 through December 31, 2002, on a quarter by quarter basis,
and for the period January 1, 2003 through December 31, 2008, on an
annual basis, the budget for the development of the Licensed Products for
posterior uveitis, DME and wet ARMD, including both the costs incurred
and to be incurred by Licensee and by Licensor; and
(b) The Agreement hereby is amended as follows: (1) Exhibit 6.1 attached
hereto is incorporated into and made a part of the Agreement and shall
replace any Budget previously agreed to by the parties; (2) Sections 5.3
and 6.2 hereby are amended by changing the date December 31, 2003 to
December 31, 2008; (3) Sections 5.8 and 7.3 hereby are amended by
changing references to the year 2003 to 2008; (4) for purposes of the
fifth sentence of Section 6.1, for any fiscal quarter that falls within a
year for which funding is set forth in Exhibit 6.1 on an annual basis,
Licensee shall pay to Licensor, for that upcoming fiscal quarter, one
quarter of the amount set forth in the Budget for payment to Licensor for
the year in which that fiscal quarter falls; (5) the first sentence of
Section 8.2 hereby is amended by deleting the words "the Immusert Product
(Cyclosporine) when approved for
1
uveitis in a Market ("Immusert")" and substituting therefor the words
"the first CDS Licensed Product when approved in a Market by the
applicable regulatory authority for sale for uveitis (the "Uveitis
Product")"; and (6) Sections 8.2, 8.3 and 15.1.5 are amended by
substituting the words "Uveitis Product" for "Immusert" or "Immusert
Product" wherever those terms appear in those sections.
(c) In all other respects, the provisions of the Agreement remain in full
force and effect.
This agreement may be executed in any number of counterparts, each of which
shall be deemed to be an original document, and all of which taken together
shall constitute one and the same agreement.
Control Delivery Systems, Inc.
By: /s/ Xxxx Xxxxxx
-------------------------------------
Xxxx Xxxxxx
President and Chief Executive Officer
Agreed and Accepted:
Bausch & Lomb Incorporated
By: /s/ Xxxxxxx X. XxXxxxxx
-------------------------------------------------
Xxxxxxx X. XxXxxxxx
Senior Vice President and Chief Financial Officer
2
